Defining the Impact of Immunotherapy for MCC - prIME Oncology
Infographic
Infographic

Defining the Impact of Immunotherapy for MCC

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View this interactive prIME Infographic to learn more about the latest data regarding the management of advanced Merkel cell carcinoma (MCC), including the emerging uses of checkpoint inhibitors for the treatment of MCC, as well as diagnosis, use of radiation, surgery, and the current role for chemotherapy. This program also features world-renowned experts adding key information and insight.

IME

IME

Release Date

Release Date

Nov 25, 2017

Expiration Date

Dec 31, 2018

  • Jürgen Becker, MD, PhDGerman Cancer Research Forum (DKTK)
    Medical University Hospital Essen
    Essen, Germany
  • Axel Hauschild MD, PhDUniversity of Kiel
    Schleswig-Holstein, Germany
  • Caroline Robert, MD, PhDGustave Roussy
    Villejuif, France
  • Brief overview of MCC
  • Clinical presentation, including diagnostic and prognostic tools
  • Current and emerging uses of checkpoint inhibitors for MCC
  • Ongoing clinical trials of PD-1/PD-L1 inhibitors
  • prIME Points™

This educational activity is specifically designed to meet the needs of healthcare providers involved in the therapeutic management of patients with Merkel cell carcinoma, including oncologists, dermatologists, surgeons, nurses, and researchers.

After successful completion of this educational activity, participants should be able to:

  • Describe the clinical presentation of MCC, as well as describe currently available diagnostic and prognostic tools
  • Compare recent evidence and ongoing clinical trials of PD-1/PD-L1 inhibitors with established options for patients with MCC

This educational activity is supported by a grant from Merck KGaA and Pfizer.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.